phenol has been researched along with Chronic Disease in 23 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors describe the case of a previously healthy 36-year-old woman who presented with a chronic myelopathy due to the progressive development of a giant spinal arachnoid cyst that resulted after the intrathecal injection of phenol for the management of chronic upper extremity pain." | 7.74 | Chronic myelopathy due to a giant spinal arachnoid cyst: a complication of the intrathecal injection of phenol. Case report. ( Khandji, AG; Komotar, RJ; McCormick, PC; Mocco, J; Olarte, M; Rincon, F, 2008) |
| "Retrobulbar phenol injection was used as a neurolytic to manage blind chronically painful eyes in ten patients." | 7.68 | Retrobulbar phenol injection in blind painful eyes. ( Birch, M; Brittain, P; Sandford-Smith, J; Strong, N, 1993) |
| "To investigate the safety of single and repeated multilevel injections of botulinum toxin (BoNT) alone or a combination of phenol and BoNT performed under general anesthesia in children with chronic muscle spasticity." | 3.74 | Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. ( Ajizian, SJ; Kolaski, K; Koman, LA; Passmore, L; Pasutharnchat, N; Smith, BP, 2008) |
| " The authors describe the case of a previously healthy 36-year-old woman who presented with a chronic myelopathy due to the progressive development of a giant spinal arachnoid cyst that resulted after the intrathecal injection of phenol for the management of chronic upper extremity pain." | 3.74 | Chronic myelopathy due to a giant spinal arachnoid cyst: a complication of the intrathecal injection of phenol. Case report. ( Khandji, AG; Komotar, RJ; McCormick, PC; Mocco, J; Olarte, M; Rincon, F, 2008) |
| "Renal cortical phenol injection provokes acute sympathetic nervous system-dependent hypertension and a shift of proximal tubule Na(+)/H(+) exchanger isoform 3 (NHE3) and Na(+)-P(i) cotransporter type 2 (NaPi2) to apical microvilli." | 3.72 | Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance. ( Campese, VM; Leong, PK; McDonough, AA; Perianayagam, A; Yang, LE; Zhong, H, 2003) |
| "Retrobulbar phenol injection was used as a neurolytic to manage blind chronically painful eyes in ten patients." | 3.68 | Retrobulbar phenol injection in blind painful eyes. ( Birch, M; Brittain, P; Sandford-Smith, J; Strong, N, 1993) |
| "Chronic abdominal pain is a common clinical problem in primary care, and is usually referred to gastroenterologists or general surgeons." | 2.44 | [Pain originating from the abdominal wall: a forgotten diagnostic option]. ( Garrido Gómez, E; Milicua Salamero, JM; Moreira Vicente, V; Riesco López, JM; Rivero Fernández, M; Rodríguez Gandía, MA, 2007) |
| "Most of the patients treated had pain due to malignant disease." | 1.26 | Chronic pain problems. Experience in a pain clinic. ( Erskine, WA; Melvill, RL, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (17.39) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Papagianni, O | 1 |
| Argyri, K | 1 |
| Loukas, T | 1 |
| Magkoutis, A | 1 |
| Biagki, T | 1 |
| Skalkos, D | 1 |
| Kafetzopoulos, D | 1 |
| Dimou, C | 1 |
| Karantonis, HC | 1 |
| Koutelidakis, AE | 1 |
| Steele, SR | 1 |
| Perry, WB | 1 |
| Mills, S | 1 |
| Buie, WD | 1 |
| Kolaski, K | 1 |
| Ajizian, SJ | 1 |
| Passmore, L | 1 |
| Pasutharnchat, N | 1 |
| Koman, LA | 1 |
| Smith, BP | 1 |
| Al-Hilli, Z | 1 |
| Deasy, J | 1 |
| Keaveny, J | 1 |
| Pollitt, CI | 1 |
| Salota, V | 1 |
| Leschinskiy, D | 1 |
| Yang, LE | 1 |
| Zhong, H | 1 |
| Leong, PK | 1 |
| Perianayagam, A | 1 |
| Campese, VM | 1 |
| McDonough, AA | 1 |
| Mangieri-Omps, L | 1 |
| Yelland, MJ | 2 |
| Mar, C | 1 |
| Pirozzo, S | 1 |
| Schoene, ML | 2 |
| Vercoe, P | 1 |
| Rivero Fernández, M | 1 |
| Moreira Vicente, V | 1 |
| Riesco López, JM | 1 |
| Rodríguez Gandía, MA | 1 |
| Garrido Gómez, E | 1 |
| Milicua Salamero, JM | 1 |
| Dagenais, S | 1 |
| Del Mar, C | 1 |
| Fullerton, BD | 1 |
| Rincon, F | 1 |
| Mocco, J | 1 |
| Komotar, RJ | 1 |
| Khandji, AG | 1 |
| McCormick, PC | 1 |
| Olarte, M | 1 |
| Erskine, WA | 1 |
| Melvill, RL | 1 |
| Birch, M | 1 |
| Strong, N | 1 |
| Brittain, P | 1 |
| Sandford-Smith, J | 1 |
| Christiansen, RG | 1 |
| Klaman, JS | 1 |
| Antila, H | 1 |
| Kirvelä, O | 1 |
| Lewis, RN | 1 |
| Felton, PM | 1 |
| Weaver, TD | 1 |
| Dechow, E | 1 |
| Davies, RK | 1 |
| Carr, AJ | 1 |
| Thompson, PW | 1 |
| Pasquinelli, C | 1 |
| Melegari, M | 1 |
| Villa, E | 1 |
| Seidenari, M | 1 |
| Scaglioni, PP | 1 |
| Tiribelli, C | 1 |
| Crocé, LS | 1 |
| Manenti, F | 1 |
| Bertrand, P | 1 |
| Lhoste, P | 1 |
| Khatib, A | 1 |
| Pillet, J | 1 |
| Dubas, F | 1 |
| Cox, R | 1 |
| Worth, PH | 1 |
| Dobrogowski, J | 1 |
| Kuś, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Laser Hair Removal for Primary Treatment of Pilonidal Disease Requiring Surgical Intervention[NCT03949140] | 22 participants (Actual) | Interventional | 2019-02-18 | Completed | |||
| Rotator Cuff Tendinopathy: A Randomized and Blinded Comparison of Superficial and Deep Injection Methods[NCT01402011] | 77 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| The Efficacy of Prolotherapy in Osteoarthritic Knee Pain[NCT00085722] | Phase 1/Phase 2 | 98 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were asked about pain at rest, at work, doing sports. The maximum pain reported on a scale ranging from 0 (no pain at all) to 10 (extreme pain) was recorded for each participant. Maximum of pain scores rest, work, sport recorded. Calculated as pain at baseline - pain at 9 months. (NCT01402011)
Timeframe: baseline and 9 months
| Intervention | units on a scale (Mean) |
|---|---|
| 25% Dextrose in Ligaments and Tendons | 2.9 |
| .1% Lidocaine in Ligaments and Tendons | 1.8 |
| .1% Lidocaine Subcutaneous | 1.3 |
Subject marks his pain level at rest, at work, doing sports on a 10 cm scale. Maximum of pain scores rest, work, sport recorded. Calculated as pain at baseline - pain at 3 months. VAS scale is from 0 = no pain to 10 = maximum pain (NCT01402011)
Timeframe: baseline and three months
| Intervention | units on a scale (Mean) |
|---|---|
| 25% Dextrose in Ligaments and Tendons | 3.0 |
| .1% Lidocaine in Ligaments and Tendons | 2.7 |
| .1% Lidocaine Subcutaneous | 2.7 |
Phone call asking how satisfied were they with their treatment 10 = extremely satisfied, 0 = extremely dissatisfied ) (NCT01402011)
Timeframe: Nine months after first injection treatment appointment
| Intervention | units on a scale (Mean) |
|---|---|
| 25% Dextrose in Ligaments and Tendons | 6.7 |
| .1% Lidocaine in Ligaments and Tendons | 4.7 |
| .1% Lidocaine Subcutaneous | 3.9 |
Subject marks his pain level at rest, at work, doing sports on a 10 cm scale. The maximum pain level among the 3 different activities was recorded. (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit
| Intervention | units on a scale (Mean) |
|---|---|
| 25% Dextrose in Shoulder Entheses | 7.3 |
| .1% Lidocaine in Shoulder Entheses | 6.9 |
| .1% Lidocaine Subcu. Above Shouldr Enth. | 6.9 |
http://www.dash.iwh.on.ca/assets/images/pdfs/DASH_quest06.pdf 30 questions assessing ability to use shoulder in everyday activities, each question scored 1 to 5, where one is normal, no problem and five is unable to perform. No data was collected at 9 months. The score ranges from 30 to 150. Higher scores represent worse outcomes. (NCT01402011)
Timeframe: 20 minutes before the first injection and at 3 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 3 months | |
| .1% Lidocaine in Ligaments and Tendons | 71.3 | 54.7 |
| .1% Lidocaine Subcutaneous | 69.6 | 61 |
| 25% Dextrose in Ligaments and Tendons | 72.4 | 61.3 |
From Steven W. Brose, DO, Michael L. Boninger, MD, Bradley Fullerton, MD, Thane McCann, MD, From: Jennifer L. Collinger, BSE, Bradley G. Impink, BSE, Trevor A. Dyson-Hudson, MD Shoulder ultrasound abnormalities, physical examination findings, and pain in manual wheelchair users with spinal cord injury. Arch Phys Med Rehabil 2008 Nov; 89:2086-93, appendix 1 12 parameters of shoulder examination: Biceps tendon/bicipital groove tenderness, Supraspinatus tendon/greater tuberosity tenderness Acromioclavicular joint tenderness Resisted external rotation. Resisted internal rotation. Supraspinatus test. Painful Arc Test. Neer impingement sign. Hawkins-Kennedy impingement sign. O'Brien Active Compression Test for AC Joint Pathology O'Brien Active Compression Test for Labral Pathology impingement sign. each test scored 0 = no pain, 1 = tenderness, 2 = pain. All 12 scores added. Range 0-24. Higher scores = more pathology (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit and at 3 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 3 months | |
| .1% Lidocaine in Ligaments and Tendons | 13.1 | 10.7 |
| .1% Lidocaine Subcutaneous | 13 | 12.9 |
| 25% Dextrose in Ligaments and Tendons | 13.2 | 11.4 |
"From Brose et al. shoulder ultrasound abnormalities, physical examination findings, and pain in manual wheelchair users with spinal cord injury Arch Phys Med Rehabil 2008 Nov, 89: 2086-93 appendix 2. rates biceps tendinopathy (0-6), supraspinatus tendinopathy (0-5), greater tuberosity the cortical surface (0-3), dynamics supraspinatus impingement (0-3), dynamic subscapularis/ biceps/ coracoid impingement (0-3). The total score ranged from 0 to 20 with higher scores indicating a worse outcome. The change was calculated by taking the final score - the baseline score." (NCT01402011)
Timeframe: 20 minutes before first injection on first day of patient visit and at on average 9.4 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | change at 9.4 +/- 2.2 months | |
| .1% Lidocaine in Ligaments and Tendons | 4.3 | -0.6 |
| .1% Lidocaine Subcutaneous | 4.3 | -0.6 |
| 25% Dextrose in Ligaments and Tendons | 4.0 | -0.3 |
3 reviews available for phenol and Chronic Disease
| Article | Year |
|---|---|
Prolotherapy injections for chronic low-back pain.
Topics: Chronic Disease; Combined Modality Therapy; Exercise Therapy; Glucose; Glycerol; Humans; Injections; | 2004 |
[Pain originating from the abdominal wall: a forgotten diagnostic option].
Topics: Abdominal Pain; Abdominal Wall; Anesthetics, Local; Chronic Disease; Hematoma; Hernia, Abdominal; Hu | 2007 |
Prolotherapy injections for chronic low-back pain.
Topics: Chronic Disease; Combined Modality Therapy; Exercise Therapy; Glucose; Glycerol; Humans; Injections; | 2007 |
2 trials available for phenol and Chronic Disease
| Article | Year |
|---|---|
The use of combined suprascapular and circumflex (articular branches) nerve blocks in the management of chronic arthritis of the shoulder joint.
Topics: Aged; Aged, 80 and over; Anesthetics, Local; Arthritis, Rheumatoid; Chronic Disease; Female; Humans; | 1999 |
A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Chronic Disease; Double-Blind Method; Female; Glucose | 1999 |
18 other studies available for phenol and Chronic Disease
| Article | Year |
|---|---|
Postprandial Bioactivity of a Spread Cheese Enriched with Mountain Tea and Orange Peel Extract in Plasma Oxidative Stress Status, Serum Lipids and Glucose Levels: An Interventional Study in Healthy Adults.
Topics: Adult; Antioxidants; Biomarkers; Blood Glucose; Cardiovascular Diseases; Cheese; Chronic Disease; Ci | 2021 |
Practice parameters for the management of pilonidal disease.
Topics: Abscess; Anti-Bacterial Agents; Anti-Infective Agents, Local; Chronic Disease; Combined Modality The | 2013 |
Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population.
Topics: Age Factors; Anti-Dyskinesia Agents; Anti-Infective Agents, Local; Botulinum Toxins; Cerebral Palsy; | 2008 |
Flank hernia secondary to phenol nerve block.
Topics: Abdominal Pain; Abdominal Wall; Aged, 80 and over; Autonomic Nerve Block; Chronic Disease; Hernia, A | 2010 |
Chemical neurolysis of the superior hypogastric plexus for chronic non-cancer pelvic pain.
Topics: Chronic Disease; Endometriosis; Female; Humans; Hypogastric Plexus; Nerve Block; Pelvic Pain; Phenol | 2011 |
Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance.
Topics: Animals; Blood Pressure; Chronic Disease; Hypertension; Immunoblotting; Immunohistochemistry; Inject | 2003 |
More advice for chronic skin conditions.
Topics: Acetone; Administration, Cutaneous; Boric Acids; Chronic Disease; Colloids; Dermatitis; Humans; Pati | 2003 |
High-resolution ultrasound and magnetic resonance imaging to document tissue repair after prolotherapy: a report of 3 cases.
Topics: Adolescent; Adult; Anesthetics, Local; Ankle Injuries; Athletic Injuries; Chronic Disease; Female; G | 2008 |
Chronic myelopathy due to a giant spinal arachnoid cyst: a complication of the intrathecal injection of phenol. Case report.
Topics: Adult; Arachnoid Cysts; Chronic Disease; Female; Humans; Injections, Spinal; Pain; Phenol; Sclerosin | 2008 |
Chronic pain problems. Experience in a pain clinic.
Topics: Chronic Disease; Hospital Departments; Humans; Injections, Spinal; Nerve Block; Pain; Pain Managemen | 1981 |
Retrobulbar phenol injection in blind painful eyes.
Topics: Adult; Aged; Aged, 80 and over; Blindness; Chronic Disease; Female; Humans; Injections; Male; Middle | 1993 |
Successful treatment of phenol poisoning with charcoal hemoperfusion.
Topics: Blood Proteins; Charcoal; Chronic Disease; Female; Hemoperfusion; Humans; Kidney Failure, Chronic; K | 1996 |
Neurolytic thoracic paravertebral block in cancer pain. A clinical report.
Topics: Acute Disease; Adult; Aged; Analgesics; Anesthetics, Local; Bupivacaine; Chronic Disease; Female; Fo | 1998 |
Phenol and alcohol chemical matrixectomy in diabetic versus nondiabetic patients. A retrospective study.
Topics: 2-Propanol; Adult; Aged; Burns, Chemical; Cautery; Chronic Disease; Diabetes Complications; Diabetes | 1999 |
Detection of hepatitis B virus transcripts in patients with chronic liver disease.
Topics: Biopsy; Blotting, Northern; Chronic Disease; DNA Probes; DNA, Viral; Guanidine; Guanidines; Hepatiti | 1990 |
[Multiradicular impairment of the lower limbs after phenol sympathectomy].
Topics: Aged; Arteriosclerosis Obliterans; Chronic Disease; Female; Humans; Leg; Phenol; Phenols; Spinal Ner | 1989 |
Chronic retention after extratrigonal phenol injection for bladder instability.
Topics: Aged; Chronic Disease; Female; Humans; Phenol; Phenols; Urinary Incontinence; Urination Disorders | 1986 |
[Our experience with epidural chemical neurolysis in the treatment of chronic pain syndromes].
Topics: Anesthesia, Epidural; Chronic Disease; Humans; Nerve Block; Pain, Intractable; Phenol; Phenols | 1985 |